Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience

Esther Rossi; Maurizio Martini; Sara Capodimonti; Tonia Cenci; Patrizia Straccia; Basilio Angrisani; Costantino Ricci; Paola Lanza; Celestino Pio Lombardi; Alfredo Pontecorvi; Luigi Maria Larocca; Guido Fadda

doi:10.1002/cncy.21416

Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience

Esther Rossi, Maurizio Martini, Sara Capodimonti, Tonia Cenci, Patrizia Straccia, Basilio Angrisani, Costantino Ricci, Paola Lanza, Celestino Pio Lombardi, Alfredo Pontecorvi, Luigi Maria Larocca, Guido Fadda

Risultato della ricerca: Contributo in rivista › Articolo in rivista

38 Citazioni (Scopus)

Abstract

It has been generally demonstrated that the valine-to-glutamic acid substitution at position 600 (V600E) in the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) gene is an effective diagnostic/prognostic marker mainly for papillary thyroid carcinoma (PTC). The detection of this mutation typically has been achieved using DNA-based techniques. The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. The authors investigated molecular and immunocytohistochemical BRAF analyses in a prospective series of samples from patients with PTC.

Lingua originale	English
pagine (da-a)	N/A-N/A
Rivista	Cancer cytopathology
DOI	https://doi.org/10.1002/cncy.21416
Stato di pubblicazione	Pubblicato - 2014

Keywords

BRAF mutation
VE1 immunomarker
immunochemistry
liquid-based cytology
thyroid papillary carcinoma

Accesso al documento

10.1002/cncy.21416

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{e0eb0a3ef9f2496e8b0a2857d6a8f283,

title = "Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience",

abstract = "It has been generally demonstrated that the valine-to-glutamic acid substitution at position 600 (V600E) in the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) gene is an effective diagnostic/prognostic marker mainly for papillary thyroid carcinoma (PTC). The detection of this mutation typically has been achieved using DNA-based techniques. The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. The authors investigated molecular and immunocytohistochemical BRAF analyses in a prospective series of samples from patients with PTC.",

keywords = "BRAF mutation, VE1 immunomarker, immunochemistry, liquid-based cytology, thyroid papillary carcinoma, BRAF mutation, VE1 immunomarker, immunochemistry, liquid-based cytology, thyroid papillary carcinoma",

author = "Esther Rossi and Maurizio Martini and Sara Capodimonti and Tonia Cenci and Patrizia Straccia and Basilio Angrisani and Costantino Ricci and Paola Lanza and Lombardi, {Celestino Pio} and Alfredo Pontecorvi and Larocca, {Luigi Maria} and Guido Fadda",

year = "2014",

doi = "10.1002/cncy.21416",

language = "English",

pages = "N/A--N/A",

journal = "Cancer cytopathology",

issn = "1934-662X",

publisher = "JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, USA, NJ, 07030",

}

TY - JOUR

T1 - Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience

AU - Rossi, Esther

AU - Martini, Maurizio

AU - Capodimonti, Sara

AU - Cenci, Tonia

AU - Straccia, Patrizia

AU - Angrisani, Basilio

AU - Ricci, Costantino

AU - Lanza, Paola

AU - Lombardi, Celestino Pio

AU - Pontecorvi, Alfredo

AU - Larocca, Luigi Maria

AU - Fadda, Guido

PY - 2014

Y1 - 2014

N2 - It has been generally demonstrated that the valine-to-glutamic acid substitution at position 600 (V600E) in the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) gene is an effective diagnostic/prognostic marker mainly for papillary thyroid carcinoma (PTC). The detection of this mutation typically has been achieved using DNA-based techniques. The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. The authors investigated molecular and immunocytohistochemical BRAF analyses in a prospective series of samples from patients with PTC.

AB - It has been generally demonstrated that the valine-to-glutamic acid substitution at position 600 (V600E) in the v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) gene is an effective diagnostic/prognostic marker mainly for papillary thyroid carcinoma (PTC). The detection of this mutation typically has been achieved using DNA-based techniques. The recently introduced monoclonal V600E antibody (clone VE1) is likely to be an alternative strategy for detecting this mutation in thyroid lesions. The authors investigated molecular and immunocytohistochemical BRAF analyses in a prospective series of samples from patients with PTC.

KW - BRAF mutation

KW - VE1 immunomarker

KW - immunochemistry

KW - liquid-based cytology

KW - thyroid papillary carcinoma

KW - BRAF mutation

KW - VE1 immunomarker

KW - immunochemistry

KW - liquid-based cytology

KW - thyroid papillary carcinoma

UR - http://hdl.handle.net/10807/55521

U2 - 10.1002/cncy.21416

DO - 10.1002/cncy.21416

M3 - Article

SN - 1934-662X

SP - N/A-N/A

JO - Cancer cytopathology

JF - Cancer cytopathology

ER -

Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experience

Abstract

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo